Cargando…
Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease
For many neurological and psychiatric diseases, novel therapeutics have been elusive for decades. By focusing on attention interference in Alzheimer's disease (AD), we provide a future vision on how emerging mobile, computer, and device‐based cognitive tools are converting classically noisy, su...
Autores principales: | Leurent, C, Ehlers, MD |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052022/ https://www.ncbi.nlm.nih.gov/pubmed/26272508 http://dx.doi.org/10.1002/cpt.212 |
Ejemplares similares
-
Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease
por: Cummings, J, et al.
Publicado: (2015) -
Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development
por: Gibbs, John P., et al.
Publicado: (2017) -
Sharing Historical Trial Data to Accelerate Clinical Development
por: Yin, Perry T., et al.
Publicado: (2019) -
Short Assessment of Health Literacy (SAHL) in Portugal: development and validation of a self-administered tool
por: Pires, Carla, et al.
Publicado: (2018) -
Histopathological assessment of laterality defects in zebrafish development
por: Chowdhury, Md. Ashraf Uddin, et al.
Publicado: (2021)